Wangmi Liu

Abstract Senescent cells (SnCs) are increasingly recognized as key contributors to osteoarthritis, with conventional strategies centered on their elimination. However, senolytic approaches face mounting limitations, driving the need for refined interventions. Here, we exploit SnCs’ lipid metabolic signature to develop a senotherapeutic strategy.

1 Introduction The increasing prevalence of spinal degeneration, affecting older adults disproportionately, is a significant global health challenge due to population aging. Spinal degeneration can lead to conditions like spinal stenosis, spondylolisthesis, and degenerative scoliosis, resulting in chronic pain, decreased mobility, and a diminished quality of life [1]. The rising demand for healthcare services, including surgical interventions, strains healthcare resources and escalates costs [2].